Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations.

Human pathology - 1 Aug 2018

Toth Laura N, de Abreu Francine B, Tafe Laura J

Abstract excerpt

Isocitrate dehydrogenases 1 and 2 (IDH1/2) are important metabolic enzymes that convert isocitrate to α-ketoglutarate. IDH1/2 mutations are associated with the development of multiple malignancies. In this study, we examine the prevalence and features of non-small cell lung cancers (NSCLC) with IDH1/2 mutations. From May 2013 to March 2017, 800 lung cancer samples were successfully sequenced for somatic mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Oncogenes

Share to Prognosis

Source

Identifiers

PMID: 29723602
DOI: 10.1016/j.humpath.2018.04.014

Genes

IDH1
KRAS
IDH2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations.PMID 29723602Read ↗

A new functional IDH2 genetic variant is associated with the risk of lung cancer.Semantic proximity Read ↗

Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes.Semantic proximity Read ↗

Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer.Semantic proximity Read ↗

Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies.Semantic proximity Read ↗

Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants.Semantic proximity Read ↗

Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.Semantic proximity Read ↗

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical PerspectivesSemantic proximity Read ↗

IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.Semantic proximity Read ↗

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution.Semantic proximity Read ↗

IDH2 -Mutated Sinonasal Tumors: A Review.Semantic proximity Read ↗

Landscape of IDH1/2 mutations in Chinese patients with solid tumors: A pan-cancer analysis.Semantic proximity Read ↗

Driver gene mutations of non-small-cell lung cancer are rare in primary carcinoids of the lung: NGS study by ion Torrent.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.